Foster City, CA, United States of America

Orit Foord

This inventor holds 78 USPTO granted patents and 17 published patent applications, plus 9 CIPO patents and 18 EPO patents, primarily in Cancer Immunotherapy (CPC class C07K). Top assignees: Abbvie Stemcentrx LLC, Stemcentrx, Inc., Amgen Fremont Inc.. Active years: 2007-2025.

USPTO Granted Patents = 78 (Patent Applications = 17)

% Patents Active = 57.7

CIPO Patents = 9 (Patent Applications = 13)

EPO Patents = 18 (Patent Applications = 33)

Average Co-Inventor Count = 7.0

ph-index = 11

Forward Citations = 625(Granted Patents)

Forward Citations (Not Self Cited) = 565(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

25 out of 40

Abbvie Stemcentrx LLC

Trellis Bioscience, Inc.

Adicet Therapeutics, Inc.

Trellis Rsv Holdings, Inc.

Celldex Therapeutics Limited

13. 1 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

Areas of Expertise:

Engineered T-Cells

Antibody Drug Conjugates

Gamma Delta T-Cells

High Affinity Antibodies

HLA-A2 Binding

PTK7 Modulators

CD324 Antibodies

DLL3 Antibodies

Cancer Treatment

Cytomegalovirus

Selective Expansion

Epidermal Growth Factor

78 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12371663 - Engineered γδ T-cells (2025-07-29),

2. 12364714 - Methods for selective expansion of gamma delta t-cell populations and compositions thereof (2025-07-22),

3. 12221480 - Methods for selective expansion of delta-3 gamma delta T-cell populations and compositions thereof (2025-02-11),

4. 11492411 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2022-11-08),

5. 11485785 - Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof (2022-11-01),

6. 11299708 - Methods for selective expansion of γδ T-cell populations and compositions thereof (2022-04-12),

7. 11135245 - Engineered γδ T-cells (2021-10-05),

8. 11033634 - Light chain variable regions (2021-06-15),

9. 10836831 - Anti-PTK7 antibodies and methods of use (2020-11-17),

10. 10533051 - Anti SEZ6 antibodies and methods of use (2020-01-14),

11. 10508153 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2019-12-17),

12. 10137204 - Anti-DLL3 antibody drug conjugates for treating cancer (2018-11-27),

13. 10118968 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2018-11-06),

14. 10087258 - Anti-CD324 monoclonal antibodies and uses thereof (2018-10-02),

15. 10053511 - Anti-claudin antibodies and methods of use (2018-08-21),

Title: Orit Foord - Innovator in Immunology and Cancer Treatment

Introduction

Orit Foord, based in Foster City, CA, is a prominent figure in the field of immunology with an impressive portfolio of 76 patents. His groundbreaking work has contributed significantly to advancements in cancer treatment, particularly focusing on T-cell therapies.

Latest Patents

Foord's latest innovations include patents for methods aimed at the selective expansion of delta-3 gamma delta T-cell populations. This patent pertains to agents that bind to a specific epitope related to δ3 γδ TCR, expanding the potential applications of these T-cells for therapeutic uses. Another notable patent is for antibodies that target deletion mutants of the epidermal growth factor receptor, specifically the type III deletion mutant, EGFRvIII. This invention is particularly important for developing diagnostic and therapeutic formulations, making strides in the fight against cancer.

Career Highlights

Throughout his career, Orit Foord has made significant contributions while working with notable companies such as AbbVie and Stemcentrx, LLC. His expertise in developing innovative therapies has placed him at the forefront of medical research, significantly enhancing the treatment landscape of various diseases.

Collaborations

Foord has collaborated with esteemed professionals in the field, including Robert A Stull and Scott J Dylla. These collaborations have fostered an environment of innovation, leading to significant advancements in cancer therapy and immunology.

Conclusion

Orit Foord's extensive patent portfolio and his work with leading companies highlight his integral role in advancing immunological therapies. His contributions are paving the way for more effective treatments and offer hope for patients in need of innovative medical solutions.